BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks
If approved, aflibercept 8 mg will be second ophthalmology medicine developed by Regeneron
https://finance.yahoo.com/news/aflibercept-8-mg-bla-treatment-120000822.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.